U of U Bioengineers Detect Early Signs of Tendon, Ligament Damage – Utah Business

Salt Lake CityBy the time someone realizes they damaged a ligament, tendon or cartilage from too much exercise or other types of physical activity, its too late. The tissue is stretched and torn and the person is writhing in pain.

But a team of researchers led by University of Utah bioengineering professors Jeffrey Weiss and Michael Yu has discovered that damage to collagen, the main building block of all human tissue, can occur much earlier at a molecular level from too much physical stress, alerting doctors and scientists that a patient is on the path to major tissue damage and pain.

This could be especially helpful for some who want to know earlier if they are developing diseases such as arthritis or for athletes who want to know if repeated stress on their bodies is taking a toll.

The scientific value of this is high because collagen is everywhere, Yu said. When we are talking about this mechanical damage, were talking about cartilage and tendons and even heart valves that move all the time. There are so many tissues which involve collagen that can go bad mechanically. This issue is important for understanding many injuries and diseases.

The teams research, funded by the National Institutes of Health, was published this week in the latest issue of Nature Communications. The paper can be viewed here.

Before, scientists thought collagenwhich are strands of protein braided into a ropelike structure that give tissue its strength and stiffnesswould just stretch or slide by each other during repeated stress and never knew if they actually got damaged. As a result, patients who put repeated stress on their body would not know if they were on the road to something worse from tough physical activity.

But now the team discovered that the collagen molecule does in fact get unraveled at a molecular level before complete failure of the tissue occurs. This type of minor damage, called subfailure damage, is associated with common injuries to connective tissues such as ligament and meniscus tears and various types of tendinitis such as tennis elbow and rotator cuff tendinopathy.

Accumulation of subfailure damage can go on for a long time with no catastrophic failure, but repeated damage results in inflammation, said Weiss. So this vicious cycle continues, the inflammation breaks down the tissue, making it more susceptible to damage, which then can result in a massive tear.

The team used a new probe called collagen hybridizing peptide (CHP), a tiny version of collagen that binds to unraveled strands of damaged collagen, to figure out where and how much damage has occurred in overloaded tendons.

This paves the way for medical researchers to use CHP probes in the future as a way of diagnosing if a person has damaged collagen and if so, how much and where, before a massive tear happens. Weiss and Yu also believe it can be used as a way to deliver drugs straight to the damaged tissue because the CHP targets only the damaged collagen. Finally, it will tell doctors even more about what happens to our bodies during repeated physical activity.

A fundamental understanding of the loads and strain that cause molecular damage has eluded us until now, said Weiss. Our findings can translate into recommendations for athletes on how to train or what rehabilitation protocols people who are injured can use.

Co-authors include researchers in the Department of Bioengineering at the University of Utah (Jared Zitnay, Yang Li, Boi Hoa San and Shawn Reese) and the Department of Civil and Environmental Engineering at Massachusetts Institute of Technology (Markus Buehler, Zhao Qin and Baptiste DePalle. The CHP probe has been commercialized by 3Helix, Inc, based in Salt Lake City, Utah.

Excerpt from:
U of U Bioengineers Detect Early Signs of Tendon, Ligament Damage - Utah Business

The anatomy of a Street Fighter Eurogamer.net – Eurogamer.net

Capcom reveals the 20-year-old guide it still uses today.

By Wesley Yin-Poole Published 04/04/2017

Capcom has published scans of a 20-year-old guide it still uses today when creating Street Fighter characters.

That's Demitri Maximoff from Darkstalkers on the cover.

At GDC last month, Capcom's Toshiyuki Kamei delivered a talk on the art direction of Street Fighter 5. As part of it, he discussed Anatomy: A Strange Guide for Artists, a document created 20 years ago around the time Darkstalkers was being made.

This document was edited by legendary Capcom artist Akira "Akiman" Yasuda, who intended for it to help teach the company's artists the rules of exaggerated anatomical features to be followed when making cool-looking pixel art.

Now, Capcom has published scans of the guide on its website, and while the accompanying text is in Japanese, we still get a decent idea of what Anatomy: A Strange Guide for Artists is all about.

The cover shows Demitri from the Darkstalkers series, and inside we see figure drawings similar to the style of Andrew Loomis, the American illustrator, alongside notes.

"It explains shortcuts and rules about how we take musculature and a character's frame and make a sprite out of it," Kamei explained during his GDC talk.

"If you exaggerate this part of the musculature it looks cool, or if you make this part slimmer it can be more efficient in the visual language. There are a lot of different rules.

"Even though this is over 20 years old, having this information about what's important and not important is still used today."

Kamei revealed an example of how this guide was used in the creation of Street Fighter 5 characters.

"When you're looking at an arm from the front, the rule is the upper arm should be thinner than the lower arm," he explained. "But when looking at it from the side, that same arm should look narrow in the forearm and wider for the upper arm.

"By following this one rule you can convey a lot of information about how this character is extending their arm, whether they're doing a straight punch or an uppercut in a really short amount of time."

Capcom created a Street Fighter 5 prototype that used photo-realistic visuals and realistic proportions, but found it made the game harder to play, so it stuck with a more exaggerated style for the game.

It's really cool to see scans of Anatomy: A Strange Guide for Artists, and get a peek behind the curtain of how Capcom's fighting games are made. Credit to Akiman, then, for his early days work on establishing the rules that would help in the creation of fighting games for the next 20 years.

Read the rest here:
The anatomy of a Street Fighter Eurogamer.net - Eurogamer.net

Genetic errors associated with heart health may guide drug development – Science Daily

Genetic errors associated with heart health may guide drug development
Science Daily
A new study of such "beneficial" genetic mutations, led by Washington University School of Medicine in St. Louis, may provide guidance on the design of new therapies intended to reduce the risk of heart attacks. The study is published March 29 in the ...
Gene mutation could help develop drug to reduce heart attacksCardiovascular Business

all 3 news articles »

See the rest here:
Genetic errors associated with heart health may guide drug development - Science Daily

Meningitis bacteria adapting to STI niche, genetic analysis shows – Medical Xpress

April 3, 2017 The growth of Neisseria meningitidis colonies on New York City Medium Agar. Credit: Wikipedia

Neisseria meningitidis, a bacterium usually associated with meningitis and sepsis, is the cause of a recent cluster of sexually transmitted infections in Columbus, Ohio and in other US cities. The bacterium appears to be adapting to a urogenital environment, an analysis of the organism's DNA shows.

The DNA analysis helps doctors track the spread of this type of bacteria, distinguish it from others, anticipate which vaccines might be protective, and understand how it has evolved.

The findings are scheduled for publication in PNAS.

Genetic changes make this "clade" of N. meningitidis look more like relatives that are known to cause gonorrhea, says lead author Yih-Ling Tzeng, PhD, assistant professor of medicine (infectious diseases) at Emory University School of Medicine.

In particular, the bacteria have lost their outer coat-capsules, potentially enhancing their ability to stick to mucosal surfaces in the body, and have gained enzymes that promote growth in a low-oxygen environment.

Some good news is that the capsule-less organism is less likely to cause invasive diseases such as meningitis, because the capsule protects the bacteria against components of the immune system found in the blood, Tzeng says.

N. meningitidis is carried at the back of the nose and throat, without symptoms, in 5 to 10 percent of people. As its name suggests, when N. meningitidis invades other parts of the body, it can cause meningitis, an infection of the lining of the brain and spinal cord, as well as deadly bloodstream infections.

In 2015, N. meningitidis began to appear in heterosexual men coming to the Sexual Health Clinic in Columbus as the cause of urethritis: inflammation leading to painful urination. These infections were initially presumed to be gonorrhea, caused by N. gonorrhoeae. More than 100 cases have been reported in Columbus, and the same type of N. meningitidis infection has appeared in Michigan, Indiana and Georgia.

Jose Bazan, DO, the Clinic's medical director and assistant professor of medicine (infectious diseases) at Ohio State University and Abby Norris Turner PhD, assistant professor of medicine (infectious diseases) teamed up with Tzeng and David Stephens, MD, professor of medicine of Emory University School of Medicine, and colleagues from Indiana University School of Medicine and the Centers for Disease Control and Prevention (CDC) to investigate.

The Columbus clinic is part of the CDC's nationwide Gonococcal Isolate Surveillance Project (GISP), which monitors antibiotic resistance. Emory co-authors include Carlos del Rio, MD, professor of medicine and global health and director of the Atlanta GISP laboratory, and Timothy Read, PhD, associate professor of medicine and human genetics.

The scientists looked at the genomes of 52 N. meningitidis samples from Columbus, and two from Indianapolis and two from Atlanta. All 56 genomes had many common features, so they're closely related, but they are continuing to evolve.

N. meningitidis is usually classified by serogroups, based on the structure of the capsule. . Vaccines against the A, C, Y, and W serogroups have been available in the US for years, and vaccines against serogroup B were introduced in 2014.

Outbreaks of N. meningitidis serogroup C meningitis and sepsis have been observed in several countries among men who have sex with men. In contrast, the bacteria described in the PNAS paper could not be assigned to any serogroup based on initial screening tests.

The loss of several genes for synthesizing components of the capsule explains the blank result, Tzeng says. However, clues in the DNA of the capsule-less bacteria make them look like they were originally derived from a serogroup C ancestor.

It is possible that vaccines that were approved in the last few years against the B serogroup might still be effective against this meningococcal clade, because the capsule-less bacteria continue to produce other proteins targeted by those vaccines, the scientists found. A vaccine against gonorrhea has been a challenge, because repeat infections are common.

N. meningitidis doesn't usually encounter low-oxygen conditions, but this clade, linked to urethritis, has picked up genes that help them to grow in the environment of the urogenital tract. Based on their sequences, the genes appear to have come directly from N. gonorrhoeae, suggesting that on at least one occasion, the two types of bacteria were in the same place and exchanged DNA.

"All the urethritis patients responded to standard treatments for gonorrhea and there were no alarming resistance markers," Tzeng says. "However, as the gene conversion demonstrates, this clade can readily take up DNA from gonococci and it is not unthinkable that gonococcal antibiotic resistance genes could jump into this clade by gene transfer, if it is to its advantage."

Explore further: Harmless bacteria may be helpful against meningococcal outbreaks

More information: Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen, PNAS, http://www.pnas.org/cgi/doi/10.1073/pnas.1620971114

Nasal drops of harmless bacteria can inhibit a related bug that sometimes causes meningococcal disease, according to new findings published online in Clinical Infectious Diseases. The studyconducted among college students, ...

University of York scientists have shed new light on why teenagers and young adults are particularly susceptible to meningitis and septicaemia.

Scientists at Oxford University have identified the key groups of bacteria responsible for the majority of meningococcal disease cases in England and Wales over the past 20 years.

A study conducted by UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) scientists shows greatly improved protective antibody responses to a new mutant vaccine antigen for prevention of disease caused by ...

Simon Fraser University researcher Lisa Craig is part of an international team that has uncovered new details about a microbe that invades the brain, sometimes with fatal results. The information is a critical piece of the ...

A team of international researchers has moved a step closer to developing a vaccine to protect against middle ear infection, currently the most common infection in children under the age of five. The vaccine could also be ...

Neisseria meningitidis, a bacterium usually associated with meningitis and sepsis, is the cause of a recent cluster of sexually transmitted infections in Columbus, Ohio and in other US cities. The bacterium appears to be ...

Flare-ups in chronic obstructive pulmonary disease, the UK's fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 people conducted by The ...

In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.

A study, published in the American Journal of Respiratory and Critical Care Medicine, describes a new treatment pathway for antibiotic resistant bacteria and infectious diseases with benefits for patients and health care ...

(Medical Xpress)A team of researchers with the Icahn School of Medicine at Mount Sinai in New York City has found that mice who have survived a dengue or West Nile viral infection fare worse when subsequently infected ...

About half of all women will experience urinary tract infections in their lifetimes, and despite treatment, about a quarter will develop recurrent infections within six months of initial infection.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:
Meningitis bacteria adapting to STI niche, genetic analysis shows - Medical Xpress

DSM ‘excited’ by biotechnology opportunites, president says – FoodBev.com

The president of DSM Food Specialties, Ilona Haaijer, has told FoodBev that shes really excited to be able to offer laboratory and scale-up facilities as part of its new biotechnology centre in the Netherlands.

The company unveiled the Rosalind Franklin Biotechnology Center on its Delft campus earlier, where more than 400 scientists will advance the companys research into food enzymes, cultures, bio-preservatives and taste ingredients for the global food industry.

Alongside significant investments in robotics and automation, the centre includes space for start-ups to explore and scale up their concepts in partnership with DSM Food Specialties.

At the opening: Alex Clere

There was a general buzz, a sense of excitement at the unveiling of DSMs imposing glass biotechnology centre this morning. DSMs scientists had already moved in, keen to give visitors an impression of the new equipment some the result of millions of euros worth of investment and collaborative spaces in action.

Ahead of the unveiling ceremony, DSM Food Specialties president Ilona Haaijer told me which of the companys products she thought were particularly pertinent, given the state of the food industry at the moment.

Its MaxiLact product, which removes lactose from a product while delivering additional sugar reductions, was flying, she said. And the Preventase proprietary enzyme allows brands to limit the amount of acrylamide in bakery items amid widespread concern across Europe.

This new centre, a major achievement for DSM Food Specialties, will help the business continue to meet the industrys biggest trends and satisfy changes to consumer preference.

The Rosalind Franklin Biotechnology Center is part of DSM Food Specialties network of more than 30 laboratories in ten countries. According to Gerhard Wagner, the director of DSMs Biotechnology Center, the company has sought to align itself with local technology hubs like Boston, Massachusetts and put down roots close to its markets.

Haaijer also noted that the world was becoming an increasingly volatile, uncertain, complex and ambiguous (VUCA) place, which made the prediction of future trends difficult.

The process was no longer as linear as it had once been, becoming an art, not a science.

But in that challenge was the opportunity for DSM to increase its participation with external stakeholders, like Delft University of Technology and Corbion.

The biotechnology centre in Delft has also been designed with the help of DSMs scientists, and includes features and open spaces deliberately intended to encourage cooperation and collaboration between employees.

Haaijer claimed that it was more and more important to open up with chief operating officer Cindy Gerhardt adding that this was the only way companies can be early to market with a product.

The Rosalind Franklin Biotechnology Center will play a crucial role in that strategy.

See the original post:
DSM 'excited' by biotechnology opportunites, president says - FoodBev.com

Apostle Inc, a Biotechnology Company for Early Cancer Detection, is Founded in the Silicon Valley – Yahoo Finance

SUNNYVALE, Calif., April 3, 2017 /PRNewswire-iReach/ -- Three business and scientific leaders with early-stage investors today announced the formation of Apostle Inc, a biotechnology company developing a novel bioinformatics-enabled nanotechnology aimed for early cancer detection. This new approach will enable the early assessment of the cancerous signals in human peripheral blood plasma, which is believed to have a significant impact on the global healthcare landscape in both developed countries and emerging markets.

Dr. David Dongliang Ge, an experienced business and scientific leader who was President of BioSciKin Co. and Director of Bioinformatics at Gilead Sciences, will lead the new company. He is joined by two colleagues as co-founders of Apostle and his investment partners. "Biotechnologies, especially those focusing on novel diagnostic or therapeutic advancements aiming for cancer, are among the key focuses in the global economy for the next 5-20 years. By 2020, the market size ofcancerdiagnosis is estimated to reach $168.6 billion. Apostle represents one of these focuses." Dr. Ge said. "With a groundbreaking bioinformatics-enabled nanotechnology approachwe want to inform the general population that we are able to help them identify cancer signals, earlier and more accurate than conventional techniques, and potentially advise their doctors to take highly effective surgical actions. "

"It's been a great pleasure to have the opportunity to work with David and his team on this amazing venture. We're thrilled to work with this scientifically imaginative and visionary company." One of the investors said. Apostleis funded by Amino Capital, ShangBay Capital, Westlake Ventures in the Silicon Valley and a group of individual investors from both the Silicon Valley and China. Apostle is advised by Dr. Charles Cantor, an American molecular geneticist, former director of the Department of Energy Human Genome Project, a member of the National Academy of Sciences, as well as Dr. Hongyu Zhao, the Ira V. Hiscock Professor of Biostatistics and Professor of Statistics and Genetics, Chair of the Biostatistics Department and the Co-Director of Graduate Studies of the Inter-Departmental Program in Computational Biology and Bioinformatics at Yale University.

About Apostle Inc.

Apostle Inc is a biotechnology company in Sunnyvale, CA. It's in the business of the research, development, licensing, and sales of novel bioinformatics-enabled nanotechnologies and the related intellectual properties, products, and services for diagnosis and treatment of human diseases

About the founder team of Apostle Inc.

Dr. David Dongliang Geis CEO and President of Apostle. Previously, he was President of BioSciKin Co. and Simcere Diagnostics Co., two global biotechnology companies headquartered in Nanjing, China. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences, where he founded and provided leadership to the bioinformatics group. Dr. Ge and his group led the phylogenomic analytical support for the critical regulatory approval of Sovaldi, a world-leading anti-HCV drug. In 2014 and 2015, Dr. Ge was invited to be a member of the U.S. NHGRI Special Emphasis Panel. He was appointed as Assistant Professor of Biostatistics and Bioinformatics at Duke University School of Medicine. He received his Ph.D.ofBiostatistics and Genetic Epidemiology from Peking Union Medical College and Chinese Academy of Medical Sciences in 2004. Dr. Ge's work in discovering the IL28B genetic variants associated with the clinical treatment responses, published in Nature in 2009, has received over 3000 times of citations with the U.S. FDA's citation in its several guidance for industry. The invention was licensed to LabCorp and QuestDiagnostics,and has become clinical diagnostic services since then (LabCorp 480630 and Quest AccuType IL28).Dr. Ge has authored over 70 original articles, including 5 in Nature and 1 in Science, in total receiving over 15,000 citations. Dr. Ge was named by the U.S. Genome Technology magazine as one of the "Rising Stars" in 2009, and by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015.

Read More

Bo Zhang, Ph.D.is VP of Chemistry of Apostle. Dr. Zhang received his Ph.D.ofChemistry from Stanford University in 2015 and received his B.S.ofChemistry from Peking University in 2010. Dr. Zhang has won the Gold Medal of National Chemistry Olympiad of China in 2006. Dr. Zhang has 10 years of experience in nanotechnology research, with outstanding achievements in developing novel nanomaterials with unique fluorescence characteristics. Dr. Zhang published over 30 original paperson Nature Medicine, Nature Materials, Nature Photonics, Nature Communications, etc. Dr. Zhang's two articles in Nature Medicine about novel nano-platform for type 1 diabetes and Zika virus infection diagnosis have attracted worldwide attention. Dr. Zhang has been PI for research projects funded by the NIH. He holds many patents. Dr. Zhang was the recipient of Materials Research Society Awards, Mona M. Burgess Fellow, William S. Johnson Fellowship, etc.

Xin Guo, Ph.D.is VP of Bioinformatics of Apostle. Previously, Dr. Guo was group leader at Gilead Sciences, in charge of the clinical phylogenomic program for developing Sovaldi. Dr. Guo received his Ph.D. in Computer Sciences from Duke University and M.S. in Informatics from Max Planck Institute of Germany. He received his B.S. in Informatics from Chiba Institute of Technology of Japan. Dr. Guo has over 10 years of experience in the R&D ofhigh performancecomputing, machinelearningand artificial intelligence. Dr. Guo has extensive experience in product development of complex algorithms and databases, with applications in genomic big data.

Wenqi Zeng, MD,PhD, FACMGis Chief Medical Advisor of Apostle. He is Chief Medical Officer of Simcere Diagnostics Co. Previously, Dr. Zeng was Senior Director of Molecular Genetics at Quest Diagnostics and was Director of Clinical Genomics at Ambry Genetics. Dr. Zeng was fellow of Clinical Molecular Genetics and Medical Genetics at Harvard. He received his M.D. from Xiang-Ya Medical School in China and Ph.D. in MolecularPatholgy/Molecular Genetics fromUniversityof Otago. He holds Diploma of American Board of Medical Genetics and Genomics(ABMGG),and is a qualified CAP inspection team leader, and a qualified CAP CLIA lab director in CA,FLand MD. He also has NY state COQ in molecular genetics and molecular oncology.

Media Contact: Public Relations, Apostle, Inc, Apostle, Inc, 650-483-5437, pr@apostlebio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

Originally posted here:
Apostle Inc, a Biotechnology Company for Early Cancer Detection, is Founded in the Silicon Valley - Yahoo Finance

University of Florida/Sid Martin Biotechnology Institute Receives … – PR Newswire (press release)

ALACHUA, Fla., April 3, 2017 /PRNewswire/ --Sid Martin Biotechnology Institute (SMBI), the leading biotechnology incubator at the University of Florida, has been awarded the Randall M. Whaley Incubator of the Year award for 2017, the highest award given by the International Business Innovation Association (InBIA). InBIA is the world's leading organization for advancing business incubation, acceleration and entrepreneurship. SMBI was named Incubator of the Year among more than 7,500 incubators worldwide. The annual award, sponsored by the Friends of the University Science Center in Philadelphia, recognizes the top global business incubation program and includes a cash prize.

The award was presented on March 28th at the InBIA's 31st Annual International Conference on Business Incubation. Accepting the award for SMBI were Mark S. Long, Director, and Merrie Shaw, Assistant Director. SMBI also received another award, the 2017 Technology/Science Entrepreneurship Center Program.

David L. Day, Assistant Vice President for Technology Transfer at the University of Florida, said, "We are honored for the Institute to be recognized as the best in the world incubator. It is a tribute to our staff and their outstanding efforts helping startups grow great innovations and new solutions into successful businesses that will make the world a better place."

SMBI has a biotechnology focus, and over the past 21 years has served more than 100 startup companies in biotechnology, biomedicine and bioagriculture. The Institute has created more than 2,200 high-tech jobs since its inception, and SMBI resident companies have accumulated over $1.62B in capital and M&A activity. There is a 93% survival rate for companies that entered the SMBI program since March of 2003, and an overall 78% survival rate for all companies served over the past 21 years.

Since becoming Director of SMBI in January 2016, Long has overseen the admission of 13 new companies, and the graduation of three companies. "We continue to see the growth of North Central Florida as a biotech hub," said Long. "As part of the University of Florida's Research Foundation, we are able to offer new biotechnology startups a tremendous wealth of resources, advisement and equipment. We are proud to be recognized by our peers as the top incubation program in the world."

About Sid Martin Biotechnology Institute at the University of Florida

The Sid Martin Biotechnology Institute (SMBI) is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. SMBI has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit sidmartinbio.org.

Contact:Merrie Shaw, Assistant Director, Sid Martin Biotechnology Institute, 386-462-0880, mashaw@ufl.edu, sidmartinbio.org

Related Files

Sid Martin Biotechnology Institute-Logo.png

Mark Long, Director, and Merrie Shaw, Assistant Director, Sid Martin Biotechnology Institute 2017 InBIA Awards.jpg

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/university-of-floridasid-martin-biotechnology-institute-receives-2017-top-global-incubator-award-from-the-international-business-innovation-association-300433133.html

SOURCE Sid Martin Biotechnology Institute at the University of Florida

http://sidmartinbio.org

Read more from the original source:
University of Florida/Sid Martin Biotechnology Institute Receives ... - PR Newswire (press release)

Global Biochemistry Analyzers Market 2017- URIT Medical … – First Newshawk

The Biochemistry Analyzers Market 2017 Research Report investigates a thorough and complete study on Biochemistry Analyzers industry volume, market Share, market Trends, Biochemistry Analyzers Growth aspects, wide range of applications, Utilization ratio, Supply and demand analysis, manufacturing capacity, Price durinf Forecast period from 2017 to 2022

The research report labeled Global Biochemistry Analyzers Market 2017 presents the penetrating study of Biochemistry Analyzers market globally, concentrating on complete analysis of the present and past historical details of Biochemistry Analyzers market. The competitive landscape view of the Biochemistry Analyzers industry is also covered in this research document.

Request Report Sample Here: https://market.biz/report/global-biochemistry-analyzers-market-2017/71705/#inquiry

Competitive Study of Global Biochemistry Analyzers Market 2017 Based on Key Vendors:

1 URIT Medical Electronic 2 Rayto Life and Analytical Sciences 3 ELITechGroup 4 Rayto Life and Analytical Sciences 5 EKF Diagnostics 6 Shenzhen Genius Electronics 7 Spinreact 8 Mindray

The report organizes the Biochemistry Analyzers market across the globe into distinct portion based on industry standards. It also distinguishes the market based on geographical regions. The report mainly throws light on dominant players in the regions of (United States, EU, China, and Japan). Other regions can be added accordingly.

Discrete aspects of the Biochemistry Analyzers industry like value chain analysis, Biochemistry Analyzers industry rules and policies, the factors driving the growth of the market and the constraints hampering the growth are explained.

In next section, the Biochemistry Analyzers report mentions the products that are currently available in the market along with their cost structures, manufacturing volume, requirement and supply analysis, import/export scenario and their overall contribution to the Biochemistry Analyzers market revenue globally.

Buy Complete Report Here (To Get Instant access): https://market.biz/report/global-biochemistry-analyzers-market-2017/71705/

Further, the report analyzes the feasibility of investment, investment return analysis and shows a complete picture of market development scope and business strategies followed by leading Biochemistry Analyzers industry players along with their company profile, market share and contact information.

Lastly, the report enlists the vital conclusions that will assist all individuals who have a keen interest in Biochemistry Analyzers Market.

Read the rest here:
Global Biochemistry Analyzers Market 2017- URIT Medical ... - First Newshawk

Anatomy of a fake scandal, ginned up by right-wing media and Trump – Washington Post (blog)

President Trump started off this morning as he often does, by settling in to watch the festival of nincompoopery that is Fox & Friends. On the show, he saw something that he believes vindicates the bizarre and false charge he made that Barack Obama was tapping his phones during the presidential campaign.

Ill try to sort through the substance of all this. But I also want to make a broader argument about how Trumps support system inside his government but especially in the conservative media and on Fox, which is where he apparently gets most of his intelligence information is playing to his worst instincts, harming him politically, and making his presidency even more dangerous.

Todays antics all started with a report on Fox & Friends in which correspondent Adam Housley reported that a high-ranking Obama administration official had requested the unmasking of the names of Trump officials who were caught up in surveillance of foreign targets. Ordinarily, when a U.S. person shows up in such surveillance say, talking to a Russian ambassador whose communications are being monitored that persons identity is blacked out in reports on the surveillance. While Housley did not identify the Obama administration official, he did say that Trump associates were being picked up by this surveillance for a year before Trump took office.

Then we get this report from Eli Lake, identifying former national security adviser Susan Rice as the Obama official who requested the unmasking. Id like to highlight this passage:

Rices requests to unmask the names of Trump transition officials does not vindicate Trumps own tweets from March 4 in which he accused Obama of illegally tapping Trump Tower. There remains no evidence to support that claim.

But Rices multiple requests to learn the identities of Trump officials discussed in intelligence reports during the transition period does highlight a longstanding concern for civil liberties advocates about U.S. surveillance programs. The standard for senior officials to learn the names of U.S. persons incidentally collected is that it must have some foreign intelligence value, a standard that can apply to almost anything. This suggests Rices unmasking requests were likely within the law.

Id say that if members of the Trump team were in communication with foreign actors who were under surveillance, that damn sure has foreign intelligence value, and its not too surprising that the national security adviser would want to know about it. Were talking about associates of a presidential candidate communicating with representatives of a foreign power.

Lets back up for a moment and go through the series of events here to get some context. Heres what has happened, with the caveat that some of the information is sketchy:

1. On March 4, President Trump sends out a series of tweets claiming that Barack Obama tapped his phones, apparently because of an article Trump saw on Breitbart. In subsequent days, the FBI director, the NSA director, the former director of national intelligence and everyone in any position to know make clear that not only didnt Obama tap Trumps phones, the president has no power to order phone-tapping.

White House press secretary Sean Spicer has been repeatedly defending President Trump's unproven claims that former president Barack Obama ordered a wiretap on him in 2016. (Bastien Inzaurralde/The Washington Post)

2.Because Trump never backs down from even the most ridiculous lie, his employees and allies are now required defend his claim. So spokesperson Sean Spicer argues that because in a different tweet Trump put the words wire tapping in quotes, that means he was referring to a whole host of surveillance types and not his phones being tapped, despite the fact that he said President Obama was tapping my phones. Trump himself will later pick up this argument.

3.Two White House officials, Ezra Cohen-Watnick and Michael Ellis, locate intelligence reports that include Trump officials in communication with Russians under surveillance by American intelligence agencies. The White House says they came across those reports in the ordinary course of business and were not actually looking for something that would back up Trumps claim; you can decide how plausible you find that. In any case, they then call Rep. Devin Nunes, the chair of the House Intelligence Committee, to the White House so he can view the information. Nunes then holds a news conference announcing the find and briefs Trump on what Trumps own staff has told him.

All of this was designed to allow Trump to say that he was right all along that he was being targeted by Obama, which of course he does.

4. Im skipping over some smaller developments and plenty of details. But today, we have the following series of events: Trump officials leak that Rice requested the unmasking of the identities of Trump associates who were in communication with foreigners under surveillance; those reporters publish their stories; then the president himself calls attention to them on his Twitter feed:

This particular PR maneuver is not unprecedented, but the point is this: Whats obviously of most importance to the president of the United States isnt the fact that his associates were in contact with people from Russia (or other countries) who were of sufficient interest to U.S. intelligence that they would be under surveillance, but whether or not each new detail that emerges does or does not support his idiotic tweets.

And this is why I argue that Fox and some of Trumps allies are only helping him hurt himself. Much of the time, having a supportive amen chorus has great political utility, because it helps buck up your base and disseminate the arguments youre making. But its one thing when those arguments are things like We should cut taxes or Obamacare is a disaster. Its something else when theyre trying desperately to claim that every stupid thing Trump ever said is actually true.

In this case, clinging to the idea that the Obama administration unfairly monitored the Trump campaign only encourages further investigation of what could turn out to be one of the biggest scandals in American political history. Nuness buffoonish efforts on Trumps behalf havent helped him at all. Quite the contrary, theyve made his committee utterly irrelevant and increased pressure on the Senate Intelligence Committee to conduct a thorough and objective review. Nunes has zero credibility, and so he can no longer be an asset to the White House.

But when Trump tunes in to Fox & Friends every morning, he learns that hes right about everything. He doesnt need to listen to his intelligence briefers or anyone else who might tell him something he doesnt want to hear. He can keep telling tall tales and pursuing his petty grievances. He never does anything wrong and never has to change. I shudder to think how that dynamic will play out when this administration faces its first foreign policy crisis, with untold numbers of lives at stake.

Visit link:
Anatomy of a fake scandal, ginned up by right-wing media and Trump - Washington Post (blog)

Anatomy of a Goal: Justin Meram’s Breakaway – Massive Report

Welcome to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from Columbus Crew SCs previous match.

For Week Five of the 2017 MLS Season, we take a look at Justin Merams 13th minute breakaway goal that put Crew SC up 1-0 as part of the 2-0 win over Orlando City on Saturday.

Heres a look at the finish from the Crew SC winger.

Through the first 12 minutes of the match, the Crew SC players were still trying to find their footing. Orlando employed a high press that forced Columbus goalkeeper Zack Steffen to make some difficult plays out of the back.

Merams game-winning goal starts with a Crew SC press. Above, you can see City center-back Jose Aja in position to receive a pass from goalkeeper Joe Bendik. As the pass approaches, Federico Higuain and Ola Kamara begin to press, cutting off Ajas safety valve to his goalkeeper and his movement down the field.

After dispossessing Aja, Higuain plays a pass to midfielder Wil Trapp. Here, you can see that Trapp has three options: Either Meram streaking down the left side of the field between Aja and Antonio Nocerino, Ola Kamara in an offside position near Jonathan Spector or Ethan Finlay wide rigth.

In this still shot, you can see that Finlay probably would have been the best option. Spector has yet to notice the Crew SC winger, and Trapp has a simple passing angle right into the path of Finlay.

However, Trapp opts to play the ball to an offside Ola Kamara. OCSC right back Will Johnson is able to intercept this pass and plays a simple ball to Aja.

Pay attention to the positioning of Meram and Johnson in the image above. Meram had just made a run down the left side of the pitch and Johnson had moved into the middle of the field to dispossess Trapp. The Orlando City right back may notice that Meram is unmarked, but he does not move towards the winger and instead turns back toward the Black & Gold half.

Here, Orlando striker Carlos Rivas receives a ball from Aja, and streaks down the middle of the pitch. Notice Artur running right behind Rivas.

Artur makes an incredible hustle play to get to the side of Rivas and make a clean, dispossessing tackle.

With the ball at his feet, Arturs eyes are locked downfield where he can see Kamara standing unmarked (and probably offside) between Spector and Johnson.

Here is where this goal really starts. Meram stayed in a wide left position, but Johnson (hidden under the Audi goal logo) is occupied by the streaking Kamara. You can just see that Johnsons back is turned to Meram.

As Arturs ball beats the Orlando backline, Johnson is still staring right at the Crew SC striker, insisting that Kamara is offside (he probably was). Meanwhile, Johnson has no idea that Meram started his run onside and is running unmarked at a full sprint.

Meram and Kamara are both in position to receive Arturs lofted ball. Johnson, in the magnified circle, is still upset that the linesman hasnt raised an offside flag and totally switched off from the play, walking back toward his defensive end. Spector is also calling for the offside flag, but also in a race to get between the ball and the goal. The Crew SC striker, maybe knowing that he was offside, cuts his run short so that Meram can take possession.

The Columbus winger, now in possession of the ball, has two options: He can either head right, toward the middle of the goal, to have more space to beat the Orlando goalkeeper or stay on his left foot and avoid the onrushing defender. Spectors defensive run is angled toward the middle of the goal, trying to force Meram onto his weaker (left) foot and provide Bendik with a better angle to make a save.

Spectors smart defensive play should not be overlooked. Running from the midfield, the City center back likely knows that Meram plays as an inverted winger and loves to start left but cut back to his right for a shot. Shielding Merams right foot, Spector cuts off the his path to goal, forcing Meram into a more difficult angle with his left foot in the best position to shoot.

Now, Meram must decide whether he will take a shot with his left foot or attempt to cut back on Spector and hit the Meram Meat Hook with his right foot.

Heavily shielding Merams right side, Spector makes Merams decision for him, and the Crew SC winger fires a left footed shot to the back post.

And Crew SC take a 1-0 lead.

Findings:

1. The start of this goal gives us a quick look at the Crew SC high press in action. The press lead directly to Trapp having the ball at his feet, in a position to put someone in on goal. While Trapp was unable spring Finlay or Kamara, this chance shows how effective a high press can be for Crew SC.

2. Johnson totally switched off during this play. Distracted by Kamaras (potentially) offside run, Johnson doesnt notice Meram running toward goal onside and unmarked.

3. Just like last week, Crew SC score another goal on a long pass following a breakaway. Artur played a perfectly weighted ball over the Orlando City backline to spring Meram.

4. Eschewing his traditional Meram Meat Hook, the winger hit a near perfect ball past Bendik. Spector made an incredible defensive play, taking away the Meat Hook and getting a slight deflection on Merams left-footed-shot.

View original post here:
Anatomy of a Goal: Justin Meram's Breakaway - Massive Report

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive … – Yahoo Finance

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to patients with HER2-positive breast cancer or HER2-mutated cancers. The program will provide access to neratinib for the treatment of early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors. Patients must not be able to participate in any ongoing neratinib clinical trial to qualify for Pumas expanded access program. Puma announced a Managed Access Program for neratinib outside the United States in the fourth quarter of 2016.

The U.S. Food and Drug Administration (FDA) permits expanded access to investigational drugs for treatment use for patients with serious or immediately life-threatening diseases or conditions who do not otherwise qualify for participation in a clinical trial and lack satisfactory therapeutic alternatives.

Caligor Opco LLC, which administers the Managed Access Program for neratinib, also will manage the U.S. expanded access program by providing regulatory and logistical support.

This expanded access program reflects our commitment to make neratinib available to eligible patients who lack therapeutic treatment options, said Alan H. Auerbach, Chief Executive Officer and President of Puma. As a specialist firm that focuses on early access to medicines, Caligor will facilitate access to neratinib for patients who may benefit from this therapy.

About the Neratinib Expanded Access Program

The neratinib EAP is a program for U.S. patients with early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors. This EAP is being administered on behalf of Puma by Caligor Opco LLC. U.S. healthcare professionals seeking more information about the neratinib EAP can email neratinibUS@caligorrx.com for additional information. Patients who are interested in enrolling in the neratinib EAP should speak with their physician to determine if neratinib is an appropriate option. Neratinib is an investigational agent and, as such, has not been approved by the FDA or any other regulatory agencies in any markets.

About Caligor

Caligor Opco LLC, a portfolio company of Diversis Capital, LLC, is a global company that manages the regulatory, logistics and supply chain needs for global access programs as well as the sourcing, storing and distribution of comparator drugs for clinical trials. Caligors global access programs help to meet the medical needs of patients worldwide by providing access to medicines in situations where the drug has not yet been approved, or is otherwise commercially unavailable. In addition, through its proprietary TrialAssist program, Caligor optimizes its services by providing for labeling, QP certification, storage, distribution and destruction of clinical trial and unlicensed medicines managed in the access programs. The company serves pharmaceutical and biotechnology companies from facilities in Secaucus, New Jersey and Dartford, UK, as well as strategically situated depot locations worldwide. More information is available at http://caligorrx.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Read More

Forward-Looking Statements:

This press release contains forward-looking statements, including statements regarding the expanded access program for PB272 (neratinib) for the treatment of early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Companys dependence on PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Companys drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Companys products; the Companys reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Companys dependence on licensed intellectual property; and the other risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170402005071/en/

See the original post:
Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive ... - Yahoo Finance

Prana Biotechnology and Xenetic Biosciences Expand Their … – Yahoo Finance

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Prana Biotechnology and Xenetic Biosciences both saw their company's stock prices soar on news of a broader, more global product distribution. Prana is continuing to expand its presentation of PBT-434, while Xenetic is moving ahead with its strategic planning goals to make its product technology available to a larger geographical area.

RDI Initiates Coverage:

Prana Biotechnology Limited https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences Inc. https://ub.rdinvesting.com/news/?ticker=XBIO

Prana Biotechnology advanced 37.65% to close at $3.40 on Thursday. The stock traded in a wide range between $4.58 and $2.75 during the day on a volume of 11.95 million shares traded. The company has presented new data from its Reach2HD trial at the American Neurological Association Annual Meeting held in Baltimore. Its primary candidate drug, PBT-434, demonstrated pre-clinical evidence that the drug will help with the treatment of movement disorders of patients with Parkinson's Disease.

Prana Biotechnology, an Australian company, for the half-year period ending December 31, 2016, reported total operating expenses of $6.05 million AUD, a pre-tax income of $3.65 million AUD, and a loss of $0.68 AUD per share.

Access RDI's Prana Biotechnology Research Report at: https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences accelerated to advance 44.30% to close at $5.44 on Thursday. The stock traded between $5.61 and $3.87 on volume of 180,793 shares traded. Xenetic has been aggressively promoting its products internationally, and the rise in price is due in part to it becoming a member of the NASDAQ community on March 30th. The company has been expanding its patent portfolio to a number of countries, including Europe and the United States. Currently, their major marketable product is PolyXen technology platform. The product's IP on its PolyXen technology platform will afford protection on average for the next 10 to 12 years.

The latest financial report with period ending September 30, 2016, showed the company posting $2.25 million in operating expenses, a net loss of $2.47 million, and net loss per share of $0.28 and it had about $212,000 of cash assets on its books as on September 30th.

Access RDI's Xenetic Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=XBIO

Our Actionable Research on Prana Biotechnology Limited (NASDAQ: PRAN) and Xenetic Biosciences Inc. (NASDAQ: XBIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at http://www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Read this article:
Prana Biotechnology and Xenetic Biosciences Expand Their ... - Yahoo Finance

Massive, computer-analyzed geological database reveals chemistry of ancient ocean – Science Daily

A study that used a new digital library and machine reading system to suck the factual marrow from millions of geologic publications dating back decades has unraveled a longstanding mystery of ancient life: Why did easy-to-see and once-common structures called stromatolites essentially cease forming over the long arc of earth history?

Stromatolites are contorted layers of sediment formed by microbes, and they are often found in limestone and other ancient sedimentary rocks deposited beneath oceans.

"Geologists have known for a long time that stromatolites were abundant in shallow marine environments during the Precambrian, before the emergence of multi-cellular life" more than 560 million years ago, says Jon Husson, a post-doctoral researcher and co-author of a study now online in the journal Geology. "But, stromatolites are rare in the ocean today."

The new study measures the slide in stromatolite prevalence based on descriptions of rocks sifted from more than 3 million scientific publications.

"Paleontologists have largely attributed the decline in stromatolites to the evolution of animals, starting some 560 million years ago," says Shanan Peters, a professor of geoscience at University of Wisconsin-Madison and study first author. "Many multi-cellular animals, like snails, eat microbes. The evolution of these big microbe-grazing animals hit 'reset' on the stromatolite's world. Or so the story has gone."

The new study found a weak correlation between stromatolite occurrence and the diversity of animals, but a stronger link to seawater chemistry.

"The best predictor of stromatolite prevalence, both before and after the evolution of animals, is the abundance of dolomite in shallow marine sediments," says Husson. Dolomite is a high-magnesium variety of carbonate, the type of sediment that forms limestone. Dolomite is harder to make than low-magnesium carbonate and it forms today in only a narrow range of marine environments.

When the ocean water is super-saturated with carbonate, "that can make it easier for things like stromatolites to form," says Husson. "In Lake Tanganyika [Africa], there are stromatolites forming today, even though there are animals everywhere, snails and fish. The lake is super-saturated with carbonate, and it's begging to be precipitated. The microbes come along and help it to precipitate, and the result is an abundance of stromatolites." Elevated carbonate saturation can also help the formation of dolomite, thereby driving the correlation with stromatolites found in this study.

Measuring the prevalence of stromatolites through all Earth history is difficult because counting the number of stromatolites alone is not sufficient. You must also know how many rocks could potentially have stromatolites, but do not.

The big innovation of this study is the interplay of a new type of digital library and machine reading system called GeoDeepDive with a geological database called Macrostrat. Both were spearheaded by Peters at UW-Madison.

GeoDeepDive is a digital library built on high throughput computing technology that can "read" millions of papers and siphon off specific information. To date, the GeoDeepDive library contains more than 3 million scientific publications from all scientific disciplines; some 10,000 new published papers are added daily.

Macrostrat is a database describing the known geological properties of North America's upper crust, at different times and depths.

The massive computing capacity at UW-Madison's Center for High Throughput Computing and HTCondor system, the brainchild of UW-Madison computer scientist Miron Livny, powers GeoDeepDive. Combining the digital library with the geological database allowed the researchers to estimate, at different time periods, the percentage of shallow marine rocks that actually have stromatolites.

The study began in the summer of 2015, when the third author, Julia Wilcots, a Madison-native who was then an undergraduate at Princeton, asked Peters for a summer project. "In my typical fashion I gave Julia a few options," Peters says. "She picked stromatolites, so I said, 'Okay, go do it!' With minimal help from us, she developed a working application to discover and extract every mention of stromatolites from our library."

Among 10,200 papers that mentioned stromatolites, "our program was able to extract 1,013 with a name of a rock unit, which enabled us to link stromatolite occurrences to Macrostrat," says Husson.

Wilcots did not have to travel to see stromatolites, Peters says. "In Madison, we are sitting on top of rocks recording one of the biggest rises in stromatolite abundance -- at least during the age of animals."

Scientists long ago observed that stromatolites started a long decline just before the start of the Cambrian era, but that decline represented a "fundamental question of paleobiology," Husson says. "Stromatolites are the oldest fossils that are visible to the naked eye. If you look at rock that is a billion years old, the chance for seeing evidence of life equals the chance of seeing stromatolites."

Beyond answering a fundamental question of Earth's history, the new study "allows us to do the kind of analyses that scientists used to only dream about, Peters says: 'If we could just compile all the published information on... anything!'

"Doing this study without GeoDeepDive would be all but impossible," Peters adds. "Reading thousands of papers to pick out references to stromatolites, and then linking them to a certain rock unit and geologic period, would take an entire career, even with Google Scholar. Here we got started with a talented undergrad working on a summer project. GeoDeepDive has greatly lowered the barrier to compiling literature data in order to answer many questions."

Another beauty of the big data, machine-reading approach is the baked-in capability for replication and improvement. "Now that this study has been done, we can run the stromatolite application again and again. We can refine the searches, and they will evaluate the new data that is being published all the time," Peters says. "So a rerun could make a better study, with minimal effort."

For centuries, "geologists have transferred hard-to-get information from the field to hard-to-get information in the literature," Peters says. "To achieve a broad-scale synthesis, you have to survey all of the published knowledge. There are new discoveries waiting in the scientific literature, if you can see the big picture and get all the data into one place."

Continue reading here:
Massive, computer-analyzed geological database reveals chemistry of ancient ocean - Science Daily

Jon Cooper: No chemistry concerns when Lightning’s hurt players ready to return – Tampabay.com

TAMPA Coach Jon Cooper began his post-morning-skate news conference Saturday by going through the list of Lightning players not available for that night's game against the visiting Canadiens.

C Steven Stamkos? C Tyler Johnson?

"No. No," Cooper said. "Keeping going. (C Cedric) Paquette? No. (D Jason) Garrison? No."

Later in the session, Cooper was asked whether that given the play of the young players who have stepped in from AHL Syracuse to help fuel the Lightning's late-season playoff push, is it possible that the return of Stamkos, who hasn't played since Nov. 15 because of knee surgery, or Johnson, who has missed 11 games with a lower-body injury, could upset the current chemistry in the dressing room?

"For me, in the end, I want the best players in, and when those guys are healthy and ready to go, they're going back in," Cooper said. "I do see your point of don't rock the boat when things are going well, but we lost three games in a row right before (the four-game winning streak leading into Saturday's game.)"

Cooper said he liked the way D Jake Dotchin, C Gabriel Dumont, C Yanni Gourde and company have played during the winning streak but given a choice, he wants his best players on the ice.

"In the end, wouldn't it be great to have Stamkos back? Yes. Johnson? Yes. Paquette? You just go down the list," Cooper said. "But you got to tip your cap to the players who've come up. They've been game-changers for us."

How much of a game-changer?

"These guys that have come up have really been the straw that stirred our drink," he said.

Hedman of the class

D Victor Hedman set the Lightning season record for points by a defenseman Thursday against the Red Wings when he picked up his 51st assist of the season. Hedman entered Saturday with 66 points (15 goals) to break Roman Hamrlik's mark of 65 (16-49) set in 1995-96. Dan Boyle (20-43) had 63 in 2005-06.

Doing what he can

To say coach Jon Cooper is impressed with C Gabriel Dumont is an understatement. That he was a fifth-round draft pick in 2009 might be the key to his success, Cooper said. Instead of wondering when he would reach the NHL, like some first- and second-rounders think, Dumont, 26, just worked on improving his game.

Now Dumont is taking faceoffs in the defensive zone and blocking shots.

"There's no pressure on (lower-round picks), and they just work, work, work," Cooper said. "They have to get past the hurdle of not being a high draft pick, but once they get past that, everything is infectious with the way they play. It's on (Dumont) how long this is going to last, but he continues to give me reasons to put him on the ice. Then you couple that with he's a phenomenal kid. He still just wants to learn and get better. Guys like him is a good reason why we're still hanging around (the playoff picture)."

Injury updates

C Steven Stamkos (knee), C Tyler Johnson (lower body), C Cedric Paquette (lower body) and D Jason Garrison (lower body) did not play Saturday. Cooper said Stamkos and Johnson could return on the road trip that begins Tuesday in Boston.

Jon Cooper: No chemistry concerns when Lightning's hurt players ready to return 04/01/17 [Last modified: Saturday, April 1, 2017 9:54pm] Photo reprints | Article reprints

Here is the original post:
Jon Cooper: No chemistry concerns when Lightning's hurt players ready to return - Tampabay.com

Genetic Errors Linked With Heart Health May Guide Drug Development – Bioscience Technology

Natural genetic changes can put some people at high risk of certain conditions, such as breast cancer, Alzheimers disease or high blood pressure. But in rare cases, genetic errors also can have the opposite effect, protecting individuals with these helpful genetic mistakes from developing common diseases.

A new study of such beneficial genetic mutations, led by Washington University School of Medicine in St. Louis, may provide guidance on the design of new therapies intended to reduce the risk of heart attacks.

The study is published March 29 in the Journal of the American College of Cardiology.

The researchers studied members of a family with rare mutations in a gene called ANGPTL3. The gene is known to play important roles in processing lipoproteins, molecules that package and transport fat and cholesterol through the bloodstream. Partial or complete loss of this gene was known to cause low cholesterol and triglyceride levels in the bloodstream. But whether it affects risk of heart attack was unclear.

Three of these family members those with a complete loss of this gene showed extremely low blood cholesterol and no evidence of plaque in their coronary arteries. According to the study authors, it was noteworthy that one of these patients showed no evidence of atherosclerosis despite having high risk factors for it, including high blood pressure and a history of type 2 diabetes and tobacco use.

The family members with complete loss of ANGPTL3 have extraordinarily low cholesterol, said first author Nathan O. Stitziel, M.D., Ph.D., an assistant professor of medicine and of genetics. The interesting thing about this family is the individuals with total loss of this gene had siblings with normal copies of the same gene. So we could compare people with differences in the function of this gene who are otherwise closely related genetically and share similar environments. Its an anecdotal study of one family, but we felt it might provide some insight into the effects of blocking ANGPTL3.

While the individuals with nonfunctional copies of the gene showed no coronary plaque, their siblings with working copies of the gene showed evidence of plaque in the coronary arteries, though it was not yet causing symptoms a situation that is common in the general population, according to Stitziel.

To study the gene beyond the experience of a single family, the scientists also analyzed data available from large population studies. In data from one study of about 20,000 patients, the researchers found those with a partial loss of this gene had, on average, 11 percent lower total cholesterol, 12 percent lower LDL cholesterol, and 17 percent lower triglycerides, measured in the blood, than individuals with full gene function.

Analysis of data from other large population studies showed a link between partial loss of the gene and a lower risk of coronary artery disease and an association between lower circulating levels of ANGPTL3 protein and a lower risk of heart attack.

Taken together, these findings provide support for efforts to develop drugs that inhibit ANGPTL3 in order to reduce the risk of coronary artery disease and heart attack. The same reasoning led to the development of a class of drugs known as PCSK9 inhibitors, which have recently been shown to be effective at reducing the risk of heart attack in a large clinical trial of more than 27,000 men and women.

Several years ago, researchers found natural beneficial mutations in the PCSK9 gene that lowered peoples cholesterol levels and protected them from coronary artery disease, much as mutations in ANGPTL3 seem to do. Both PCSK9 and ANGPTL3 are important in the bodys processing of cholesterol from the diet. Any drugs that inhibit them, then, work differently than commonly prescribed statins, which reduce cholesterol levels in the blood by blocking the bodys internal cholesterol manufacturing.

While reducing cholesterol levels in the blood typically is thought to be good for the heart, Stitziel pointed out that there may be dangers to inhibiting the normal function of a gene. Not all genetic mutations that result in low cholesterol in the bloodstream are healthy. For example, there is one genetic disorder in which cholesterol levels in the blood are low because cholesterol gets stuck in the liver, resulting in fatty liver disease.

We need a better understanding of how cholesterol is processed in individuals with complete loss of ANGPTL3 function before we can fully say what effect inhibiting ANGPTL3 is going to have, Stitziel said. Studies of people with mutations that completely knock out a genes function are important because they can provide insight into the potential effects both good and bad of drugs inhibiting that genes function.

Along with Washington University School of Medicine, other institutions that played key roles in the study included the Broad Institute of MIT and Harvard and the Perelman School of Medicine at the University of Pennsylvania.

Go here to see the original:
Genetic Errors Linked With Heart Health May Guide Drug Development - Bioscience Technology

Making chemistry cool – Marshall Independent

SMSU seniors Katie Carter, left, and Megan Bruns watch the student reactions as their elephant toothpaste begins to erupt.

Explosions of light and sound, disappearing water and other cool chemistry reactions despite oftentimes being awe-inspiring and mysterious are not to be mistaken for magic, members of the Southwest Minnesota State University Chem Club said.

People always call our shows magic shows, but we consider them more of reaction shows because we dont want to teach magic, SMSU chemistry major Tori Henry said. Chemistry isnt magic. Its science.

Holy Redeemer School students recently had the opportunity to learn about and experience the power of chemistry during a chemical reaction show presented by Henry, Megan Bruns, Katie Carter, Easton Popma, Austin LaFollette and Rhiannon Sears.

We enjoy doing the reactions on our own we would be fine because its fun doing it but then watching all the kids reactions out of it, its a really fun thing for us, LaFollette said.

LaFollette had the role of heating mixtures of chemicals inside a balloon, stretching out as far as he could with a long-handled torch.

Its a little exciting, he said. You never know whats going to happen. Its an art and a science. The balloons are a little bit of an art. Youre never quite sure what is going to come out.

Along with chemistry professor Noelle Beyer, the SMSU students started off the reaction show by stressing safety. Chemicals can be dangerous, so anyone working with them needs to be very knowledgeable and cautious, they said.

Most of what we do is fairly safe, Beyer said. Our reactions have come a long way. In the labs at school and at shows when were doing experiments, we say that you need to respect the chemicals. Whatever it is, treat it with respect and then youll be fine.

At certain points in the show, the presenters had everyone cup their hands over their ears. Kindergartener Aria Williamson always made sure she followed the directions. Like the other students and staff curiously observing, she knew something exciting was about to happen.

When asked which reaction was her favorite, Williamson said: The balloon one because it was so noisy. It scared me.

One time LaFollette sparked the balloon, a quick burst of light flared in the darkness. The next time he lit the chemicals inside a balloon, there were collective gasps as most audience members felt the incredible sonic blast.

I liked the explosions the best, HRS fourth-grader Wyatt Foley said.

Along with other fourth-graders under the direction of teacher Lisa Vandendriessche, Foley was required to provide some feedback about what he witnessed.

We just had to tell three things we learned about it and what experiment you like best, he said.

It was apparent that the show was intriguing for people of all ages.

This was a lot of fun, Vandendriessche said.

One of the tricks was called the Hustle because it involved disappearing liquid. LaFollette started off with three cups, one of which held a water-like fluid. As he switched the cups around, the students were asked to keep their eyes on the one that contained the water. Most were able to get the first round right. Some correctly guessed the second try. But none picked the right cup on the third switcheroo attempt because the liquid dissipated.

Its really cool to be able to see different reactions in the classroom and be able to put them into things that look really cool things that blow peoples minds, Henry said. The Hustle, the first one we did with the water, is really simple, but nobody knows what happens. The water just disappears.

Beyer said the Chem Club typically includes about 10-15 students each year. Roughly six or seven perform chemical reactions at various shows, she said.

It varies from show to show, depending on what students have going on, Beyer said. I thought this show went really well. The audience was super excited, which always gets us excited. All the reactions worked some of them take a little more time and I thought the students who were presenting did a great job explaining and trying to keep the students involved and aware.

Sometimes, Beyer said, the audiences arent as responsive to the presentations.

This was a great audience, so that was really fun, she said. We really enjoyed it.

Bruns and Carter demonstrated how to make toothpaste for an elephant.

Those of us in the Chem Club decided we should adopt an elephant, Bruns said. Thats my favorite animal. So I went to Wal-Mart to get elephant supplies.

Bruns continued, saying she bought giant blankets and wrote him a book they could read together, but there wasnt any toothpaste for elephants.

Katie and I both have recipes for toothpaste, but one of us has a higher concentration, Bruns said. See if you can tell which one of us it is.

Eventually, the toothpaste-like suds began to erupt. One experiment reacted quicker, while the other one produced suds longer.

Bruns and Henry then used a recipe to make a strong rope-like floss for the elephant.

You can see the two layers, Henry said. We resurrected this one. Wed done this demonstration in years prior, but wed stopped doing them for awhile because it didnt work. We just got it working again. Its really cool.

Henry said she couldnt believe how strong the floss was, especially considering it started out as a liquid.

When I was practicing it, I wound that whole thing up and it was about the size of a lollipop, she said. It was huge. It just kept going. And it is a really strong string.

LaFollette used chemicals to produce a glow-in-the-dark liquid like fireflies, he said. That is cool, a student said.

LaFollette then got out another balloon. This time, the reaction caused a loud boom and had enough of a ripple effect to make the overhead stage curtains sway back and forth.

That is so insane, another student in the audience said.

Music teacher Anna Lenz used the reaction show as a teachable moment.

You can smell the sulfur, Lenz said to the kindergarteners. Thats what you are smelling.

Henry demonstrated how to make snow using chemicals.

Well, it looks more like a slushy, she said. But I bet youve never lit snow on fire.

Henry did just that, changing colors as the chemicals began reacting. She also had a little sparkler show.

After Bruns added liquid to half-full glasses and changed the clear colors to red, white and blue, Beyer took the stage.

Im like Megan. Im into colors, Beyer said. I have some solutions here that are clear, and Im going to add some clear-water type chemicals that will turn different colors. Im going to turn them into a rainbow.

Beyer effectively produced the colors of the rainbow, then turned the colors back to a clear color. Wow, a handful of students said.

Beyer said the Chem Club typically does a show for and makes Silly Putty with the West Side Elementary students each year. They also did a show in Lake Benton this year. Wee Care preschool is also scheduled to come to campus for some hands-on activities this year as well.

I think its important to educate people, and especially to get kids excited, to let them know that its fun, she said. Science doesnt have to be boring and uninteresting. We just love it. Science is really cool.

Students also had the opportunity to see a number of other demonstrations, including a fire tornado and ones using large plastic water jugs. All of the experiments were met with much applause.

Since there were younger students in attendance, Beyer said they purposely left out a lot of information. No one wants inexperienced children attempting to replicate the chemistry experiments at home.

Sometimes when we do shows for a little older kids, we explain it more, Beyer said. Sometimes well do shows for high school kids. Then we try to explain more of the chemistry that is going on.

The hope is that students who are interested in science possibly pursue that avenue when they are older. Henry, a junior, didnt start out as a chemistry major, but was drawn to it.

I started out as a food science major, she said. I ended up switching, and now Ive met a lot of great friends here.

LaFollette said he contemplated becoming a veterinarian, so he started out taking biology and chemistry classes.

I found that I just enjoyed the chemistry classes and ended up in the Chem Club, too, he said. Im going to California (this week) to the American Chemicals Society Convention. Theres going to be thousands and thousands of people there.

WASHINGTON (AP) A sobering report to governors about the potential consequences of repealing the Obama-era ...

Continue reading here:
Making chemistry cool - Marshall Independent

BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC … – ETF Daily News (blog)

March 31, 2017 9:38am NASDAQ:BBC

From Zacks: After being stressed by the twin attacks of higher drug pricing and increased regulatory scrutiny, the biotech sector has made a strong comeback in the first quarter of 2017.

In fact, BioShares Biotechnology Clinical Trials ETF (BBC Free Report) tops the list of the best performing ETFs of the quarter, with impressive returns of about 27.4%. BBC carries a Zacks ETF Rank of 3 or Hold rating with a High risk outlook.

The surge in the fund was largely driven by cheap valuation, robust earnings results and a slew of positive actions taken by the President. In particular, Trump promised to reduce federal regulations by 7580% and streamline the Food & Drug Administration (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trumps proposed tax reforms and cash repatriation policy are also supporting the rally (read: Top ETF Stories of Q1 from Wall Street).

Apart from these, encouraging industry trends including the possibility of increased M&A activity, an accelerated pace of innovation, promising drug launches, growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, the growing middle class, an insatiable demand for new drugs, and ever-increasing health care spending are fueling growth in the sector.

Lets take a closer look at the fundamentals of BBC and its performance.

BBC in Focus

This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trials stage. This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index. BBC is a small cap centric fund, having amassed $24.4 million in its asset base. It charges 85 bps in fees per year from investors and trades in light average daily volume of around 14,000 shares.

Holding 70 stocks in its basket, it is widely spread out across various components with none holding more than 3.34% share. Though almost all the stocks in the funds portfolio delivered strong returns, a few were the real stars that more than doubled their size (read: Hit ETFs & Stocks from the Top Sector of February).

Below we have highlighted those five best-performing stocks in the ETF with their respective positions in the funds basket:

Best Performing Stocks of BBC

Esperion Therapeutics Inc. (ESPR Free Report) : The stock has surged about 185% so far this year and carries a Zacks Rank #3 with solid Industry rank in the top 39%. Most of the gains came on hopes of the Food and Drug Administrations (FDA) approval to the cholesterol-lowering medicine bempadoic acid. However, Esperion saw its earnings estimates deteriorating from a loss of $3.46 to a loss of $6.27 for this year over the past 90 days. It also has an unfavorable VGM Style Score of F. ESPR occupies the top spot in the funds basket with 3.3% of the total assets (see: all the Health care ETFs here).

Global Blood Therapeutics Inc. (GBT Free Report) : This stock takes the second position in the funds basket with 2.8% allocation. It has also delivered incredible returns of 169% in the first quarter on rumors of the takeover of a big pharma name like Novo Nordisk (NVO). The stock saw its earnings estimates moving from a loss of $2.89 to a loss of $2.83 for this year over last the 90 days. Further, it belong to a solid Industry with a Zacks Rank in the top 43%. The stock has a Zacks Rank #3 with a VGM Style Score of F.

TG Therapeutics Inc. (TGTX Free Report) : It currently has a Zacks Rank #3 with a VGM Style Score of F. The stock soared nearly 150% in the first quarter with most upside coming after positive study results from its phase 3 clinical trial of treatment for high-risk leukemia patients. However, TG Therapeutics saw negative earnings estimate revision of a nickel for the current year over the past 30 days and has an ugly Zacks Industry rank in the bottom 32%. The stock is the third firm and accounts for 2.7% share in BBC (read: Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs).

Cara Therapeutics Inc. (CARA Free Report) : The stock has been climbing since the start of the year and has gained about 105.5% this quarter on the pending trial results of its lead drug candidate. It hit a new one-year high of $20.90 in the last trading session after the company announced positive results from part A of a phase 2/3 trial for chronic kidney disease-associated pruritus. Cara Therapeutics has a solid Zacks Industry rank in the top 43%. However, it has a Zacks Rank #4 (Sell) with a VGM Style Score of F. The stock occupies the fourth position in the funds portfolio, making up for 2.5% share.

NewLink Genetics Corporation (NLNK Free Report) : This stock takes the seventh spot in the funds basket with 2.2% of assets. It has doubled this quarter but saw negative earnings estimate revision of $1.21 for this year over the past 90 days. NewLink Genetics currently has a Zacks Rank #3 with a VGM Style Score of F and solid Zacks Industry rank in the top 43%.

The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) was unchanged in premarket trading Friday. Year-to-date, BBC has gained 25.75%, versus a 5.59% rise in the benchmark S&P 500 index during the same period.

BBC currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #23 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Zacks Research.

Tags: biotech Equity Health Care NASDAQ:BBC Zacks

Categories: NASDAQ:BBC

Read the original here:
BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC ... - ETF Daily News (blog)

Paul Babitzke elected as Fellow of the American Academy of Microbiology – Penn State News

UNIVERSITY PARK, Pa. Paul Babitzke, professor of biochemistry and molecular biology at Penn State, has been elected as a Fellow of the American Academy of Microbiology. Election as a Fellow recognizes members of the American Society for Microbiology (ASM) who display excellence, originality and leadership and have made exceptional contributions to the advancement of microbiology.

Babitzke's research focuses on the regulation of gene expression where and when genes are used in a cell by RNA structure and RNA-binding proteins. He is interested in the fundamental mechanisms elongation and termination of how RNA molecules are transcribed from DNA, in addition to investigating a variety of genes in which RNA binding proteins control gene expression by transcription attenuation, repression of translation initiation, and/or mRNA stability.

Babitzke has been director of the Biochemistry, Microbiology, and Molecular Biology Graduate Program at Penn State since 2013 and director of the Center for RNA Molecular Biology in the Penn State Huck Institutes of the Life Sciences since 2009. He was elected as a Fellow of the American Association for the Advancement of Science in 2017 and is a member of the ASM, the American Society for Biochemistry and Molecular Biology, and the RNA society. He was the keynote speaker at the Federation of European Biochemical Societies - American Society for Microbiology Conference on the Biology of RNA in host-pathogen interactions in Tenerife, Canary Islands, Spain in 2014 and was honored with the Daniel R. Tershak Memorial Teaching Award in 2009.

Babitzke joined the faculty at Penn State as an assistant professor of biochemistry and molecular biology in 1994, became associate professor in 2000, and professor in 2006. Prior to that, he was a postdoctoral researcher in the Department of Biological Sciences at Stanford University from 1991 to 1994. Babitzke earned a doctoral degree in genetics at the University of Georgia in 1991 and a bachelors degree in biomedical science at St. Cloud State University in Minnesota in 1984.

Last Updated March 31, 2017

Read more from the original source:
Paul Babitzke elected as Fellow of the American Academy of Microbiology - Penn State News

Biochemical superglue opens new approach to vaccine development – Phys.Org

March 31, 2017 Credit: University of Oxford

An Oxford University spinout company is developing a molecular superglue for the rapid development of vaccines targeting a range of diseases.

SpyBiotech is using 'biochemical superglue' that can facilitate the rapid development of robust and novel vaccines. The company has raised 4m at launch in seed financing to develop the technology, led by Oxford Sciences Innovation with participation from GV.

The company gets its name from the bacterium Streptococcus pyogenes (Spy), the same organism behind a number of infections including strep throat and impetigo. The team behind SpyBiotech divided Spy into a peptide, SpyTag, and a protein partner, SpyCatcher. Naturally attracted to each other, the two form a covalent bond once combined.

SpyBiotech believes that this bond is the missing link to effective development and production of highly effective vaccines. The company will initially focus on virus-like particles (VLPs), a leading technology to induce immune responses by vaccination. Discovered in 1963, VLPs have become a cornerstone of a number of vaccines. Resembling viruses but without pathogenic material, VLPs can instead be coated with bug-busting antigens. However, the two most common ways in which a VLP can be paired with antigens genetic fusion and chemical conjugation are imprecise, expensive, prone to being misassembled, and consequently can result in the failure of a vaccine.

Conversely, SpyBiotech's SpyVLP can be easily and efficiently combined with a number of antigens, and used to produce stable vaccines that induce robust antibody responses. The company plans to target infectious diseases including major viral infections at first, with a view to developing SpyVLP into a universal platform that can be adapted to target a wide variety of conditions. In particular, owing to the versatile and easy-to-use nature of SpyVLP, the technology could underpin efforts to rapidly combat future outbreaks and pandemics.

SpyBiotech will use the seed funding to get its first candidates ready for Phase I trials. During that period, SpyBiotech's founders will receive support from its investors. The founders are aiming to start a further round of funding in the near future to catalyse the development of SpyVLP and expand into other disease areas. A leadership team, including the company's first CEO, will be announced in the coming months.

Sumi Biswas, Associate Professor at the Jenner Institute, Oxford University, said: 'Researchers in the vaccine field, including us, have struggled to make effective VLPs against many diseases for a long time. We view this superglue technology as a game changer to enable faster development of effective vaccines against major global diseases. We are excited to begin the journey of taking this versatile and innovative approach forward and moving our new vaccines from the laboratory to human clinical testing.'

Oxford Sciences Innovation (OSI), the patient capital investor for Oxford University, led the 4m investment, with GV (formerly Google Ventures), an independent venture capital arm of Alphabet, joining in participation.

Lachlan MacKinnon, Principal at OSI, said: 'We see the Spy technology as the missing link in rapid and robust VLP vaccine design and see GV as a natural co-investment partner to take this forward. We are privileged to be working with four founders who bring such an impressive combination of academic prowess and clinical stage experience to the company.'

Tom Hulme, General Partner at GV, added: 'SpyBiotech has established a novel approach using platform VLP vaccine technology that shows promise in a number of addressable markets. We're looking forward to working with a team of world class scientists with extensive experience in vaccine development spanning from vaccine design through to Phase II clinical trials to develop more effective vaccines for a wide range of global diseases.'

The research underpinning SpyBiotech was developed in conjunction between researchers at Oxford University's Department of Biochemistry and Jenner Institute, with four academics joining SpyBiotech at launch. The team includes: Mark Howarth, Professor of Protein Nanotechnology; Sumi Biswas, Associate Professor of Vaccinology; Simon Draper, Professor of Vaccinology; and Dr. Jing Jin. Combined, the founding team has taken twelve products to Phase I and II trials; filed nine patents on vaccines and other technologies; and has extensive experience in biotech and industrial collaborations and partnerships. The commercialisation of SpyBiotech's technology and company formation is supported by Oxford University Innovation, the research commercialisation company of Oxford University.

Carolyn Porter, Deputy Head of Technology Transfer at Oxford University Innovation, said: 'SpyBiotech punctuates research that's been developing for some time here at Oxford, and is a testament to the benefits of collaboration between our departments and institutes. Oxford is playing a leading role in developing the next generation of vaccines, and SpyBiotech and other spinouts working in this sector showcases the potential impact the University can have on the wider world.'

Explore further: Synthetic biologists use bacterial superglue for faster vaccine development

An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.

Although many infectious diseases lack vaccines, current vaccine research is limited, primarily due to an understandable but unfortunate lack of commercial interest. A new article identifies and discusses the gaps in human ...

A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer. The therapeutic platform is projected to target cancer by recruiting ...

Scientists have identified new ways to provide vaccines against polio, which do not require the growth of live virus for their manufacture.

A new method to produce a stable fragment of poliovirus could enable safer production of vaccines, according to a study published in PLOS Pathogens.

(Phys.org)A team of researchers from several institutions in China and the U.S. has developed a way to use platinummolybdenum carbide to catalytically release hydrogen from methanol and water to power a hydrogen fuel ...

Some genetic mutations can cause a virus to flourish. Others make the virus wither away, unable to function normally and reproduce. Yet other genetic mutations only show their hand under certain conditions.

(Phys.org)A team of chemists at the University of California has developed a cheaper way to functionalize unactivated alkanes (hydrocarbons such as ethane, methane and propane) by using much more abundant catalysts. In ...

High energy, ultraviolet radiation from the Sun is a known to hazard to life, yet the energy provided by our star has played an important role as the essential driver of life on Earth.

A newly developed small molecule selectively kills the pathogen causing sleeping sickness and Chagas disease. Scientists from the Helmholtz Zentrum Mnchen, along with colleagues from the Technical University of Munich and ...

Ceramic textiles, improved jet engine blades, 3-D printed ceramics and better batteries may soon become a reality, thanks to a recently patented polymer from a Kansas State University engineer.

Adjust slider to filter visible comments by rank

Display comments: newest first

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Link:
Biochemical superglue opens new approach to vaccine development - Phys.Org